Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/37939
Full metadata record
DC FieldValueLanguage
dc.contributor.authorReddy, Yogesh N., V-
dc.contributor.authorKaye, David M.-
dc.contributor.authorHandoko, M. Louis-
dc.contributor.authorvan de Bovenkamp, Arno A.-
dc.contributor.authorTedford, Ryan J.-
dc.contributor.authorKeck, Carson-
dc.contributor.authorAndersen, Mads J.-
dc.contributor.authorSharma, Kavita-
dc.contributor.authorTrivedi, Rishi K.-
dc.contributor.authorCarter, Rickey E.-
dc.contributor.authorObokata, Masaru-
dc.contributor.authorVERBRUGGE, Frederik-
dc.contributor.authorRedfield, Margaret M.-
dc.contributor.authorBorlaug, Barry A.-
dc.date.accessioned2022-08-30T08:52:59Z-
dc.date.available2022-08-30T08:52:59Z-
dc.date.issued2022-
dc.date.submitted2022-08-16T11:26:28Z-
dc.identifier.citationJAMA cardiology (Print),-
dc.identifier.urihttp://hdl.handle.net/1942/37939-
dc.description.abstractIMPORTANCE Diagnosis of heart failure with preserved ejection fraction (HFpEF) among dyspneic patients without overt congestion is challenging. Multiple diagnostic approaches have been proposed but are not well validated against the independent gold standard for HFpEF diagnosis of an elevated pulmonary capillary wedge pressure (PCWP) during exercise. OBJECTIVE To evaluate H2FPEF and HFA-PEFF scores and a PCWP/cardiac output (CO) slope of more than 2 mm Hg/L/min to diagnose HFpEF. DESIGN, SETTING, AND PARTICIPANTS This retrospective case-control study included patients with unexplained dyspnea from 6 centers in the US, the Netherlands, Denmark, and Australia from March 2016 to October 2020. Diagnosis of HFpEF (cases) was definitively ascertained by the presence of elevated PCWP during exertion; control individuals were those with normal rest and exercise hemodynamics. MAIN OUTCOMES AND MEASURES Logistic regression was used to evaluate the accuracy of HFA-PEFF and H2FPEF scores to discriminate patients with HFpEF from controls. RESULTS Among 736 patients, 563 (76%) were diagnosed with HFpEF (mean [SD] age, 69 [11] years; 334 [59%] female) and 173 (24%) represented controls (mean [SD] age, 60 [15] years; 109 [63%] female). H2FPEF and HFA-PEFF scores discriminated patients with HFpEF from controls, but the H2FPEF score had greater area under the curve (0.845; 95% CI, 0.810-0.875) compared with the HFA-PEFF score (0.710; 95% CI, 0.659-0.756) (difference, -0.134; 95% CI, -0.177 to -0,094; P < .001). Specificity was robust for both scores, but sensitivity was poorer for HFA-PEFF, with a false-negative rate of 55% for low-probability scores compared with 25% using the H2FPEF score. Use of the PCWP/CO slope to redefine HFpEF rather than exercise PCWP reclassified 20% (117 of 583) of patients, but patients reclassified from HFpEF to control by this metric had clinical, echocardiographic, and hemodynamic features typical of HFpEF, including elevated resting PCWP in 66% (46 of 70) of reclassified patients. CONCLUSIONS AND RELEVANCE In this case-control study, despite requiring fewer data, the H-2 FPEF score had superior diagnostic performance compared with the HFA-PEFF score and PCWP/CO slope in the evaluation of unexplained dyspnea and HFpEF in the outpatient setting.-
dc.description.abstractIMPORTANCE Diagnosis of heart failure with preserved ejection fraction (HFpEF) among dyspneic patients without overt congestion is challenging. Multiple diagnostic approaches have been proposed but are not well validated against the independent gold standard for HFpEF diagnosis of an elevated pulmonary capillary wedge pressure (PCWP) during exercise.OBJECTIVE To evaluate H2FPEF and HFA-PEFF scores and a PCWP/cardiac output (CO) slope of more than 2 mm Hg/L/min to diagnose HFpEF.DESIGN, SETTING, AND PARTICIPANTS This retrospective case-control study included patients with unexplained dyspnea from 6 centers in the US, the Netherlands, Denmark, and Australia from March 2016 to October 2020. Diagnosis of HFpEF (cases) was definitively ascertained by the presence of elevated PCWP during exertion; control individuals were those with normal rest and exercise hemodynamics.MAIN OUTCOMES AND MEASURES Logistic regression was used to evaluate the accuracy of HFA-PEFF and H2FPEF scores to discriminate patients with HFpEF from controls.RESULTS Among 736 patients, 563 (76%) were diagnosed with HFpEF (mean [SD] age, 69 [11] years; 334 [59%] female) and 173 (24%) represented controls (mean [SD] age, 60 [15] years; 109 [63%] female). H2FPEF and HFA-PEFF scores discriminated patients with HFpEF from controls, but the H2FPEF score had greater area under the curve (0.845; 95% CI, 0.810-0.875) compared with the HFA-PEFF score (0.710; 95% CI, 0.659-0.756) (difference, -0.134; 95% CI, -0.177 to -0,094; P < .001). Specificity was robust for both scores, but sensitivity was poorer for HFA-PEFF, with a false-negative rate of 55% for low-probability scores compared with 25% using the H2FPEF score. Use of the PCWP/CO slope to redefine HFpEF rather than exercise PCWP reclassified 20% (117 of 583) of patients, but patients reclassified from HFpEF to control by this metric had clinical, echocardiographic, and hemodynamic features typical of HFpEF, including elevated resting PCWP in 66% (46 of 70) of reclassified patients.CONCLUSIONS AND RELEVANCE In this case-control study, despite requiring fewer data, the H-2 FPEF score had superior diagnostic performance compared with the HFA-PEFF score and PCWP/CO slope in the evaluation of unexplained dyspnea and HFpEF in the outpatient setting.-
dc.description.sponsorshipFukuda Foundation for Medical Technology, Mochida Memorial Foundation;-
dc.description.sponsorshipNippon Shinyaku, Japanese Circulation Society; Takeda Science-
dc.description.sponsorshipFoundation; Axon; AstraZeneca; Corvia; Medtronic; GlaxoSmithKline;-
dc.description.sponsorshipMesoblast; Novartis; Tenax Therapeutics-
dc.language.isoen-
dc.publisherAMER MEDICAL ASSOC-
dc.titleDiagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea-
dc.typeJournal Contribution-
local.format.pages9-
local.bibliographicCitation.jcatA1-
dc.description.notesBorlaug, BA (corresponding author), Mayo Clin, Dept Cardiovasc Med, 200 First St SW, Rochester, MN 55905 USA.-
dc.description.notesborlaug.barry@mayo.edu-
local.publisher.place330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.statusIn press-
dc.identifier.doi10.1001/jamacardio.2022.1916-
dc.identifier.isiWOS:000825589900002-
dc.contributor.orcidVerbrugge, Frederik Hendrik/0000-0003-0599-9290-
local.provider.typewosris-
local.description.affiliation[Reddy, Yogesh N., V; Verbrugge, Frederik H.; Redfield, Margaret M.; Borlaug, Barry A.] Mayo Clin, Dept Cardiovasc Med, 200 First St SW, Rochester, MN 55905 USA.-
local.description.affiliation[Kaye, David M.] Alfred Hosp, Dept Cardiol, Melbourne, Vic, Australia.-
local.description.affiliation[Handoko, M. Louis; van de Bovenkamp, Arno A.] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Cardiol, Amsterdam Cardiovasc Sci, Amsterdam, Netherlands.-
local.description.affiliation[Tedford, Ryan J.; Keck, Carson] Med Univ South Carolina, Dept Med, Div Cardiol, Charleston, SC 29425 USA.-
local.description.affiliation[Andersen, Mads J.] Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark.-
local.description.affiliation[Sharma, Kavita; Trivedi, Rishi K.] Johns Hopkins Univ, Dept Med, Div Cardiol, Baltimore, MD USA.-
local.description.affiliation[Carter, Rickey E.] Mayo Clin, Dept Hlth Sci Res, Jacksonville, FL 32224 USA.-
local.description.affiliation[Obokata, Masaru] Gunma Univ, Dept Cardiovasc Med, Grad Sch Med, Gunma, Japan.-
local.description.affiliation[Verbrugge, Frederik H.] Hasselt Univ, Fac Med & Life Sci, Biomed Res Inst, Hasselt, Belgium.-
local.description.affiliation[Verbrugge, Frederik H.] Univ Hosp Brussels, Ctr Cardiovasc Dis, Jette, Belgium.-
local.uhasselt.internationalyes-
item.validationecoom 2023-
item.accessRightsClosed Access-
item.fullcitationReddy, Yogesh N., V; Kaye, David M.; Handoko, M. Louis; van de Bovenkamp, Arno A.; Tedford, Ryan J.; Keck, Carson; Andersen, Mads J.; Sharma, Kavita; Trivedi, Rishi K.; Carter, Rickey E.; Obokata, Masaru; VERBRUGGE, Frederik; Redfield, Margaret M. & Borlaug, Barry A. (2022) Diagnosis of Heart Failure With Preserved Ejection Fraction Among Patients With Unexplained Dyspnea. In: JAMA cardiology (Print),.-
item.fulltextNo Fulltext-
item.contributorReddy, Yogesh N., V-
item.contributorKaye, David M.-
item.contributorHandoko, M. Louis-
item.contributorvan de Bovenkamp, Arno A.-
item.contributorTedford, Ryan J.-
item.contributorKeck, Carson-
item.contributorAndersen, Mads J.-
item.contributorSharma, Kavita-
item.contributorTrivedi, Rishi K.-
item.contributorCarter, Rickey E.-
item.contributorObokata, Masaru-
item.contributorVERBRUGGE, Frederik-
item.contributorRedfield, Margaret M.-
item.contributorBorlaug, Barry A.-
crisitem.journal.issn2380-6583-
crisitem.journal.eissn2380-6591-
Appears in Collections:Research publications
Show simple item record

WEB OF SCIENCETM
Citations

39
checked on Apr 24, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.